A combination of broader symptom categories, such as paroxysmal symptoms, hyperkinetic symptoms, neuropsychiatric symptoms, and cognitive impairment, has been proposed to increase sensitivity in identifying patients with ATP1A3‐related disorders than relying on restricted phenotypes.1 This evidence concerns the gene ATP1A3 and Cognitive impairment.